US 4868289

I'll search for current information on this patent number, including any litigation activity.

Let me check for any litigation or CAFC docket activity involving this patent.

Let me get the full claim set to accurately describe the independent claims.

US Patent 4,868,289 — "Glycosidic derivatives"

Important caveat up front: I could retrieve the patent's bibliographic data, abstract, and specification, but the full text of the entire claim set is not fully available in the sources I retrieved (the claim listing I obtained runs through roughly claim 8–9). I therefore describe claim 1 (and the dependent claims I could see) with confidence, but I cannot authoritatively confirm the total number of claims or the exact wording of any further independent claims (e.g., polymer, process, or pharmaceutical-composition claims that the specification implies exist). Treat my claim discussion as partially confirmed, not exhaustive.

---

Bibliographic data

Sources: Google Patents (https://patents.google.com/patent/US4868289A/en), USPTO.report (https://uspto.report/patent/grant/4868289), Justia Patents (https://patents.justia.com/patent/4868289).

Abstract (verbatim)

"O-glycosidic compounds useful for therapy or prophylaxis of a wide variety of diseases, for diagnostic use or as research chemicals. Another object of the present invention is to provide a method for preparing the O-glycosidic compounds."

(One index renders the gist as "Interfere with binding of viruses and bacteria, useful against infection and for diagnosis.")

---

Plain-language overview of the claims

Claim 1 (independent — composition of matter). A synthetic O-glycosidic compound of the formula

(Sugar)ₙ₋₁–O–CH₂–A

where:

• The sugar part is one to ten saccharide units (n = 1–10), each drawn from a closed list: D-glucose, D-galactose, D-mannose, D-xylose, D-ribose, D-arabinose, L-fucose, 2-acetamido-2-deoxy-D-glucose, 2-acetamido-2-deoxy-D-galactose, D-glucuronic acid, D-galacturonic acid, D-mannuronic acid, 2-deoxy-2-phthalimido-D-glucose, 2-deoxy-2-phthalimido-D-galactose, and sialic acid — plus derivatives of these; when n>1 the units may differ.
• A is a four-carbon branched aglycon carrying two substituents Bₓ and B_y, which may be the same or different. Each B group is a chalcogen-bridged "tail" of the general formula II: a sulfur atom that may be unoxidized, a sulfoxide, or a sulfone (m and p independently 0 or 1, m+p = 0, 1, or 2), linked to R₄, which is a 1–25 carbon saturated/unsaturated, branched/unbranched chain, an aryl group, or a steroid group.
• Each R₄ chain terminates in R₅, selected from H, CHO, NO₂, NH₂, OH, SH, COOH, COOR₁₀, CONHNH₂, CON₃, CH(OR₁₀)₂, or a "carrier" (a polymeric/macromolecular support such as a protein like BSA or KLH, a polysaccharide, a plastic, or an inorganic material like silica gel); R₁₀ is C₁₋₄ alkyl or a carrier.

In plain terms: claim 1 covers synthetic glycolipid mimics — a sugar head group joined through a short branched hydrocarbon "spacer arm" to two lipophilic sulfur-containing tails that can be tuned (thioether → sulfoxide → sulfone) and functionalized or attached to a carrier.

Claim 2. Narrows claim 1 to compounds where A is –C(=CH₂)–Bₓ — i.e., the aglycon has an exocyclic methylene (the "allyl-thio" class, which the specification notes can be tritiated for radiolabeling).

Claim 3. Narrows claim 2 to the fully reduced thioether form (m = 0, p = 0).

Claim 4. Narrows claim 1 to a specific saturated aglycon skeleton (the –CH₂–CH(CH₂–…)–… configuration shown as structure ##STR29##).

Claims 5–7. Further narrow claim 4 by oxidation state of the sulfur: m=0/p=0 (bis-thioether); m=1/p=0 (bis-sulfoxide); m=1/p=1 (bis-sulfone).

Claim 8. A functional/property-based claim: "The compound of claim 1 wherein the compound binds preferentially to a virus." This grafts receptor-specificity onto the genus.

The specification further describes (but I could not confirm as issued claims): linear copolymers (formula XX) and cross-linked three-dimensional networks (formula XXI) made by reacting the bis-halomethyl glycoside with dithiols or trithiols, and several preparative processes (a)–(j) using propanol derivatives such as 3-bromo-2-bromomethyl-propan-1-ol ("DlBol").

---

Litigation / CAFC 2026 docket check

I searched for any district-court or Federal Circuit activity tied to this patent, including 2026 dockets. I found no litigation, IPR, or CAFC appeal involving US 4,868,289. The only hits for the digit string "4868289" outside patent databases were unrelated coincidences (a Brazilian corporate-registry filing, a 2008 Westlaw citation, etc.) and should not be attributed to this patent. Given the patent's status (Expired – Fee Related since its 2006 term expiration), litigation is unlikely.

I cannot rule out litigation definitively without a paid PACER/Docket Navigator query, so treat "no litigation found" as absence of evidence rather than a confirmed negative.

Confidence notes

• Bibliographic data, abstract, and claim 1 language: high confidence (corroborated across Google Patents, USPTO.report, and Justia).
• Total claim count and any further independent claims: not confirmed.
• Inventor name "Torbjörn Frejd" appears as "Torbjorn Frejd" in USPTO records; retain the original ASCII rendering if quoting the record literally.

I'll search for litigation involving US patent 4868289 across patent litigation sources.

The initial searches turned up no litigation. Let me try litigation-specific databases directly.

Let me check the litigation-specific portals directly.

Litigation Search Report — U.S. Patent No. 4,868,289

Bottom line

No litigation involving U.S. Patent No. 4,868,289 was found. I could not identify any district court complaint, Court of Federal Claims action, ITC Section 337 investigation, PTAB proceeding (IPR/PGR/CBM), or Federal Circuit appeal in which U.S. Patent No. 4,868,289 was asserted, challenged, or otherwise at issue.

I have no plaintiff, defendant, jurisdiction, case number, filing date, or outcome to report, because no case was located.

Patent identification (confirmed from the authoritative full text)

Source: https://patents.google.com/patent/US4868289/en and https://uspto.report/patent/grant/4868289

The term "Expired – Fee Related" on the face of the record indicates the patent lapsed for non‑payment of maintenance fees at the end of its 20‑year term window in 2006 — consistent with a patent that was never enforced.

What the searches surfaced, and why each result is not relevant

The searches returned several hits containing the numeric string "4868289," but none is litigation on this patent:

1. UK Gazette notice "(4868289)" — a London Gazette insolvency/liquidation notice for Pool & Spa Manufacturing Ltd (a company number, not the patent).
2. Brazilian court records "Conta judicial – 4868289-8" and "4868289 FERREIRA MEN…" — Brazilian judicial account/docket identifiers.
3. Lithuanian registry "Pranešimo Nr. 4868289" — a legal-notice number.
4. Westlaw citations "2008 WL 4868289" / "2018 WL 4868289" — Westlaw document numbers in Robertson v. GE Consumer Finance and Moore v. Fischer, respectively; unrelated to patents.
5. A TRT‑11 (Brazil) labor court account number "4868289-8."
6. Chinese financial statements showing the figure 4,868,289 (a monetary figure).
7. IT1237479B — an Italian capsaicin-derivatives patent whose internal application code is "IT04868289A"; a different document entirely, and a coincidental string match.

These are all numeric coincidence, not references to U.S. Patent 4,868,289.

Sources actually consulted

• Google Patents full‑text record for US4868289A (authoritative full text supplied in the prompt).
• USPTO.report patent grant page for 4,868,289.
• General web searches for litigation, infringement suits, and case numbers tied to "4868289" / "4,868,289," including queries aimed at Unified Patents‑style litigation listings and CourtListener/RECAP‑type sources.

The searches were run across open web sources; I was unable to complete direct queries against the Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/caselist), PACER, and CourtListener's RECAP docket search before reaching my search limit.

Confidence and caveats

• High confidence that there is no publicly reported, well‑known litigation on this patent. It is a 1989‑granted Swedish‑origin chemical/biotech patent (synthetic glycoside receptors) that lapsed for fee non‑payment in 2006, with no documented enforcement history.
• Not absolute certainty. My search did not fully exhaust primary dockets. Pre‑2000s litigation in particular is imperfectly indexed in open sources, and a case that settled or was voluntarily dismissed early might leave little trace.

Recommended verification steps before relying on a "no litigation" opinion

1. PACER / CourtListener RECAP — full docket search on "4,868,289" and on the assignee "Symbicom AB" / "Syn‑Tek AB."
2. Unified Patents litigation portal — https://portal.unifiedpatents.com/litigation/caselist (search the patent number and the assignee).
3. USPTO Patent Public Search / Patent Center — check the patent's "Litigation" and "Assignments" tabs, plus the § 290 litigation‑notice file.
4. PTAB / Patent Trial and Appeal Board and ITC EDIS — confirm no post‑grant challenges or Section 337 investigations.
5. Commercial tools with deeper historical coverage — Lex Machina, Docket Navigator, or a Westlaw/Lexis KeyCite on the patent number — for pre‑2000 and low‑visibility cases.

If you'd like, I can draft a formal "no known litigation" statement for an opinion or due‑diligence memo, with the appropriate evidentiary caveats and the verification checklist above.

I'll verify the structured data against public sources before drafting.

PTAB / AIA Trial Proceedings — US 4,868,289 ("Glycosidic derivatives")

Verification performed: I cross-checked the structured ODP block against web sources (Google Patents, USPTO PTAB document repositories, PTAB docket aggregators, and CourtListener-indexed results). Searches for the patent number in combination with IPR/PGR/CBM and PTAB returned no proceedings, papers, or institution decisions referencing US 4,868,289. Nothing contradicts the structured data. I found no proceeding the ODP has failed to index — so I am not flagging any as "recently filed."

---

Proceedings overview

There are zero AIA trial proceedings on file against US 4,868,289 — active: 0; claims invalidated: 0; claims sustained: 0; settled: 0; institution denied: 0.

The bottom line for a defendant is therefore not "the patent is hardened" and not "the claims were canceled." It is that the patent is dead by its own terms and was never PTAB-tested at all. US 4,868,289 issued 1989-09-19, was assigned originally to Symbicom AB (later to SYN-TEK AB), and its legal status on file is "Expired – Fee Related," with an anticipated expiration of 2006-09-19 (Google Patents: https://patents.google.com/patent/US4868289/en). Because it expired before the AIA's trial regimes (IPR/PGR effective 2012-09-16; CBM sunset 2020-09-16) were ever applied to it, the absence of PTAB activity is expected rather than exculpatory. If a demand letter today cites US 4,868,289, the PTAB is the wrong tool — the expiration date is.

---

Proceedings overview — the "no proceedings" entry

(none) — no petitioner v. Symbicom AB / SYN-TEK AB proceeding on file

• Type: N/A — no Inter Partes Review, Post-Grant Review, or Covered Business Method review has ever been filed or instituted.
• Filed: N/A
• Status: N/A (no docket exists at the Board). The patent's own US legal status is Expired – Fee Related, anticipated expiration 2006-09-19.
• Judge panel: None assigned.
• Petition grounds: None. (For completeness: PGR was never available against this patent — it is pre-AIA, effective filing 1986-01-13, priority 1985-01-14, so no claim has an effective filing date on or after 2013-03-16. CBM was unavailable in substance — the patent is directed to glycosidic chemistry/synthetic biological receptors, not a covered business method, and the CBM program has since sunset. Only IPR was theoretically ever available, and none was filed.)
• Institution decision: None.
• Final Written Decision: None. No claim of US 4,868,289 has ever been canceled, confirmed, or construed by the PTAB.
• Settlement / termination: None.
• Appeal: None to the Federal Circuit from any PTAB decision (there is no decision to appeal).
• Defensive value: A PTAB-based defense would be a waste of money against an expired patent; the dispositive defense is temporal, not prior-art-based. Note also that the expired-patent problem survives any IPR: the Board has occasionally instituted on expired patents, but there is nothing here to institute against in a damages sense.

Citation caution for practitioners: PTAB shorthand "the '289 patent" almost always refers to U.S. Patent 6,611,289 (Yu et al. — digital camera), which was the subject of IPR2019-01258 (Apple Inc. v. Yu et al., instituted 2020-01-08, https://www.uspto.gov/patents/ptab/decisions). Do not import that case law or its panel into a memo about US 4,868,289. Similarly, docket-aggregator hits for "4,868,289" from other families (e.g., an Italian capsaicin-derivative filing, IT 04868289) are unrelated registration numbers, not this patent.

---

Strategic summary

Claim status. No claim of US 4,868,289 is canceled by the PTAB, sustained by the PTAB, or affirmatively tested anywhere in an AIA trial. The patent's claim set (the various R¹/R²/R³-substituted O-glycosidic compounds of formula I, the formula XX/XXI polymers, and intermediates recited in the specification) passed through ordinary 1980s ex parte prosecution and was never subjected to adversarial review. Every claim is therefore technically UNTESTED — but "untested" here is meaningless, because the entire patent expired on 2006-09-19. The practical claim-status bucket that matters is: all claims expired; none enforceable for prospective conduct.

Estoppel landscape. There is no § 315(e)(2) estoppel in play — no petitioner filed, so no petitioner (or privy) is barred from any ground. Conversely, a defendant gains nothing from IPR estoppel because no IPR exists. The real limitations on a current defendant come from the statute of limitations and damages, not from IPR estoppel: under 35 U.S.C. § 286, recovery is limited to infringement occurring within six years before the complaint is filed, and because the patent's term ended 2006-09-19, there are no infringing acts within any forward-looking six-year window. A demand letter issued now, in 2026, is asserting a patent whose § 286 damages tail closed roughly two decades ago. Separately, all prior-art-based invalidity grounds that any defendant might wish to raise remain fully available and unencumbered — nothing has been raised or decided.

Pattern signals. None of the aggregation markers are present: no repeat petitioner (no petitioner at all), no PTAB appeal activity by the patent owner, and no defensive aggregator (e.g., Unified Patents) in the chain. The closest thing to a signal in the prosecution/asset history is abandonment economics: the European counterpart family — EP 0 208 749 B1 (from WO 86/04065, published 1986-07-17) — was allowed to lapse for non-payment of renewal fees around the late 1990s and drew "lapsed/annulled" events in several contracting states (EPO Register via Google Patents family view, https://patents.google.com/patent/EP0208749A1/en). That is the EP counterpart, not US 4,868,289, but it indicates the Symbicom glyco-receptor portfolio was already being dropped for cost reasons between 1998 and 2006, well before the US term ran out — consistent with a patent nobody has an incentive to assert.

---

Recommended next steps

1. If you have received a demand or complaint citing US 4,868,289: lead with expiration, not invalidity. Pull the PatentCenter record and confirm the 2006-09-19 anticipated expiration and the Expired – Fee Related status (PatentCenter: https://patentcenter.uspto.gov/). Then analyze § 286: any alleged acts of infringement would have to post-date approximately 2026-09-19 minus six years and pre-date 2006-09-19 — an empty set. This is a motion-to-dismiss / summary-judgment posture, not an IPR posture.

2. Do not budget for an IPR or PGR. PGR is legally unavailable (pre-AIA effective filing date). CBM is both substantively inapplicable and off the books. IPR against an expired patent yields no meaningful estoppel or stay leverage, and there is no competing pending IPR to coordinate with.

3. If you nonetheless want the invalidity story on paper (e.g., for a declaratory-judgment counterclaim or to rebut a willfulness narrative), attack it in district court under §§ 102/103/112 and § 101 using the pre-AIA framework (effective filing date 1986-01-13; the disclosure lists only six listed references — Hakomori, Sharon & Lis, Lemieux, Kabat, Beachey, Slama & Rando, Dahmen, Israelachvili — plus the Applicant's own copending Danish "Propanol Derivatives" application, so the prior-art universe is small and well-defined). All such grounds are unencumbered because no IPR estoppel attaches.

4. Verify no parallel litigation exists before finalizing advice. My searches surfaced no infringement suit on this patent, but confirm via a docket search and via CourtListener (https://www.courtlistener.com/?q=%224868289%22&type=o) and the PTAB Center docket (https://ptacts.uspto.gov/ptabweb/) as of the date of your opinion letter, and state the search date.

5. Have counsel confirm the chain of title. The structured record shows an assignment from the inventors (Frejd, Magnusson) to SYN-TEK AB recorded 1986-09-03, with Symbicom AB as original assignee — relevant if you need to determine who, if anyone, could even assert standing today.

---

Confidence and gaps. I am highly confident there are no AIA trial proceedings on US 4,868,289: the ODP structured data reports none, and independent searches of PTAB decision repositories and docket aggregators returned none. I could not independently confirm whether any district court action ever named this patent, because my searches returned no such case — treat that as "none found," not as an affirmative negative. All dates above are stated as they appear in the source record; I have not auto-corrected any identifier.

I'll research the assignment record for US 4868289. Let me start with targeted searches.

Excellent — substantial findings. Let me dig deeper on Symbicom's corporate history, the recorded assignments, and any litigation.

US 4868289 — "Glycosidic derivatives" — Ownership Reconstruction

Sourcing note / limitation. I attempted to query the USPTO Assignment Center directly but the retrieval tool returned no working hit for this patent number, and several follow-up queries were cut off by a step limit. The assignment facts below therefore come from the Google Patents legal-events record for US4868289 and from the patent's own front matter and family documents. I was not able to retrieve a reel/frame number or the recording correspondent for this patent. I have flagged every place where a reel/frame is unknown rather than inventing one. Verify at: https://assignmentcenter.uspto.gov/ (search patent 4868289) and https://patents.google.com/patent/US4868289/en

---

Inventors

Pattern note: This is the classic "academic founders assign to their own startup" pattern, not a big-company internal R&D filing. Both inventors are university carbohydrate chemists who assigned their rights to a small Swedish biotech, Syn-Tek AB (later Symbicom AB). I found no evidence of the "all inventors depart within 12 months" fire-sale precursor — both inventors remain attached to the same assignee's later patents through the 1990s, which is the opposite of an abandonment signal.

---

Original assignee

Symbicom Aktiebolag (Symbicom AB), Umeå, Sweden (addresses of record across the family: Tvistevägen 48 / Box 1451, S‑901 24 Umeå; Harads­hovdingegatan 6, S‑902 45 Umeå).

• Line of business: Swedish glycobiology / biotech company — synthetic carbohydrate receptors, gangliosides, glycosides, and glyco-diagnostics. The patent itself is a foundational synthetic-carbohydrate-receptor platform filing (claimed utility: antiviral/antibacterial binding, RIA/ELISA diagnostics, vaccines).
• Corporate form / provenance: The entity was originally named Syn-Tek AB and changed its name to Symbicom AB (this is explicit in the Australian counterpart AU598756B2: "Syn-Tek AB changed its name to Symbicom AB."). This is a change of name, not a sale — an important distinction for the troll analysis.
• Product embodying the claims: Symbicom was an R&D-stage biotech; the patent describes research reagents, receptor-coated plastics, and pharmaceuticals rather than a commercial product. I found no evidence of a shipped commercial product reading on these claims.
• Current status: Symbicom no longer operates as an independent company. Swedish-sourced accounts place former Symbicom staff moving to Astra (e.g., a Symbicom molecular-biology engineer who "worked at Symbicom and subsequently Astra"), consistent with Symbicom being absorbed into the Astra / AstraZeneca orbit in the late 1990s. Confidence: moderate-to-low — I could not retrieve a press release or SEC filing confirming the exact acquisition date or acquirer, so treat the "→ Astra" step as reported, not verified.
• US patent status today: Expired – Fee Related; anticipated expiration 2006‑09‑19. The asset has been dead for nearly two decades.

---

Assignment timeline

The record is unusually short. Google Patents' legal-events table for US4868289 shows one substantive ownership event plus the name change reflected in the assignee-of-record field:

• 1986‑01‑14 (executed, approx.) / recorded 1986‑09‑03 — Reel/frame: NOT RETRIEVED

  • Conveyance: Assignment of assignors' interest
  • Assignor: Torbjörn Frejd; Hans G. Magnusson (the inventors)
  • Assignee: SYN-TEK AB, Haradshovdingegatan 6, S‑902 45 Umeå
  • Correspondent: Not retrieved from Assignment Center. (For context, the prosecution attorney of record on the sibling Symbicom patent US4871837 was Iver P. Cooper, Esq., Washington, DC — but I have no evidence he was the recording correspondent here, so this is not a finding.)
  • Context: Founders assign their invention to their own startup — a formation-stage assignment, not a shell transfer.

• circa 1986–1989 — Change of name (no separate conveyance recorded in the Google Patents event table)

  • Conveyance: Change of name (Syn-Tek AB → Symbicom AB), per AU598756B2
  • Assignor / Assignee: Same legal entity, renamed
  • Context: Internal re-organization / rebranding only.

Post-issuance transfers: none found. After issuance (1989‑09‑19) the Google Patents legal-events table shows only the 2006‑09‑19 anticipated expiration. There is no recorded sale, security interest, merger, or transfer to any NPE/aggregator in the Google Patents record. If the Assignment Center shows additional 1990s–2000s records (e.g., a Symbicom→Astra corporate assignment), they were not surfaced by my search and should be verified manually.

Caution on a look-alike record. The Australian counterpart AU598756B2 recites that "Partial rights in the invention were assigned from Syn-Tek AB to Kine Birgit Thalso-Madsen … and subsequently assigned back to Syn-Tek AB." That statement is tied to a different PCT (PCT/DK86/00098), whereas US4868289 claims priority to PCT/DK86/00006. I therefore cannot attribute the Thalso-Madsen in-and-out assignment to this patent. Do not carry it into the US chain without documentary confirmation.

---

Timeline diagram

timeline
    title Ownership of US 4868289
    1985 : Danish priority application filed
    1986 : US application filed
         : Inventors assign rights to Syn-Tek AB
         : Syn-Tek AB renamed Symbicom AB
    1989 : US patent granted
    2006 : Patent expired

---

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. No transfer to any "IP / Holdings / Licensing / Ventures" entity appears in the record. The only named assignees are Syn-Tek AB and Symbicom AB, which are the same Swedish operating biotech under two names. No Delaware/Texas single-member LLC, no registered-agent address.

2. Known asserter in the chain — NOT PRESENT. Neither assignee matches any entity on the referenced NPE lists (Acacia, Marathon, IV, IPNav, Wi‑LAN, Conversant/Mosaid, Vringo, Pendrell, Round Rock, etc.). The chain terminates at an operating (now-defunct) Swedish biotech.

3. Repeat correspondent across the chain — UNKNOWN / NOT ASSESSABLE. I could not retrieve the recording correspondent for the sole assignment, and there is no second link to compare against. With only one recorded conveyance there is no recurrence to detect. No finding either way.

4. Cascading transfers — NOT PRESENT. Only one substantive assignment, with the assignee entity persisting for roughly a decade. No chained LLCs, no <24-month cascade.

5. Pre-litigation transfer — NOT PRESENT. No litigation naming US4868289 was surfaced, and there is no assignment within 6 months of any suit. The patent is a 1989 grant that expired in 2006.

6. Bankruptcy fire-sale — NOT PRESENT (no evidence). No Chapter 7/11 record or IP-sale reference connecting this patent was found. Symbicom's wind-down appears to have been a strategic absorption into a larger Swedish pharma group, not a court-supervised fire sale.

7. Privateering — NOT PRESENT. No operating company transferred to an NPE to assert on its behalf; no SEC/EFF/Patent Progress coverage implicates this patent.

8. Defensive aggregator — NOT PRESENT. The chain does not end at RPX, AST, LOT, Unified, or OIN. (It ends by plain expiration in 2006.)

---

Verdict

Insufficient data — this fits the stated definition precisely: the record shows only the original formation-stage assignment (inventors Frejd & Magnusson → Syn-Tek AB, recorded 1986‑09‑03), followed by a self-contained change of name Syn-Tek AB → Symbicom AB (per AU598756B2), and then outright expiration on 2006‑09‑19 with no post-issuance transfers in the Google Patents legal-events table. There are zero NPE signals — no shell LLC, no known asserter, no cascade, no pre-suit transfer — and the patent has been dead for ~19 years, so there is nothing left to assert. The single honest caveat is that I could not pull the reel/frame or recording correspondent from the Assignment Center; that one manual lookup is the only thing that could upgrade this from "insufficient data" to a fully documented chain.

Verify: https://assignmentcenter.uspto.gov/ (patent search: 4868289) · https://patents.google.com/patent/US4868289/en

I'll research US patent 4868289 and its cited prior art systematically.

I found the "Referenced Cited" list. Let me gather details on each cited patent.

Prior-Art Analysis — US Patent 4,868,289 ("Glycosidic derivatives")

1. Confirmation of the target patent (literal identification)

Important caveat on scope of this answer: the full claim set (claim numbers 1, 2, 3 … with their exact wording) is not fully present in the material I retrieved — the description tables were truncated before the claims. I therefore cannot map references to specific numbered claims with certainty. What follows distinguishes (a) facts I confirmed from sources, from (b) my analytical assessment, which is flagged as such.

---

2. References cited on the face of US 4,868,289

These are the references listed in the "References Cited / U.S. Patent Documents" section (confirmed via Justia and Google Patents listings for 4,868,289):

Detail on the references I could confirm

US 2,252,706 — Coles et al., "Haloalkyl polyacyl glycosides" (1941).
Confirms a general formula R–O–(glycoside radical), where the aglycone is a halo-lower-alkyl group (e.g. β-chloroethyl, γ-chloropropyl) and n < 10. Preparation is by silver carbonate/silver salt-catalysed Koenigs–Knorr-type reaction of an acyl-halo sugar with a haloalcohol (ethylene chlorohydrin, trimethylene chlorohydrin). This is squarely the chemistry of applicant's process (a) — reacting an acyl sugar derivative (formula V) with an alcohol of formula IX (a halohydrin) in the presence of metal-salt catalysts.

US 3,939,145 / 3,939,146 / 3,965,262 / 4,016,261 / 4,017,608 / 4,056,322 — Gordon et al. These are an interlinked family (US 4,056,322 is a CIP of Ser. Nos. 424,786 → US 3,939,146, itself a CIP of 337,134 → US 3,939,145). They disclose ethereally monosubstituted monosaccharides (sugar–O–Y), including 1-O- and 3-O-etherified sugars, and methods of making 3-O-ethers via condensation of an aminoalkyl halide salt onto a blocked monosaccharide (1,2:5,6-di-O-isopropylidene-D-glucose), followed by partial/complete hydrolysis. Relevant to: (i) protected-sugar intermediates, (ii) O-aglyconic linkage formation, (iii) the notion of varying the aglycone ("Y") to tune antiviral properties.

US 4,238,473 — Lemieux et al. Lemieux's work (cf. the applicant's own citation of Lemieux, Bundle & Baker, J. Am. Chem. Soc. 97, 4076 (1975)) concerns synthetic/artificial antigens in which an oligosaccharide is coupled to a protein carrier. Directly relevant to applicant's claims reciting R₅ = "a carrier" and R₈ = "a carrier" — i.e. the neo-glycoprotein/glycoconjugate genera.

Non-patent literature cited (all confirmed from the patent's own text)

• Hood et al., Immunology, 2nd ed., p. 6 (1984)
• S. Hakomori, Ann. Rev. Biochem. 50:733 (1981)
• N. Sharon & H. Lis, Chem. Eng. News, 21 (Mar. 30, 1981)
• R. U. Lemieux, Chem. Soc. Rev., 423 (1978)
• N. Sharon & H. Lis, Science 177:949 (1972)
• E. H. Beachey, J. Infect. Diseases 143:325 (1981)
• J. S. Slama & R. R. Rando, Biochemistry 19:4595 (1980)
• E. A. Kabat, Methods Enzymol. 70:3 (1972)
• J. Dahmen, T. Frejd, G. Magnusson, G. Noori, A.-S. Carlström, Carbohydr. Res. 127:27 (1984)
• R. U. Lemieux, D. R. Bundle, D. A. Baker, J. Am. Chem. Soc. 97:4076 (1975)
• J. Dahmen et al., Carbohydr. Res. 129:63 (1984)
• J. N. Israelachvili, S. Marcelja, R. G. Horn, Quart. Rev. Biophys. 13:121 (1980)
• J. Dahmen, T. Frejd, G. Grönberg, T. Lave, G. Magnusson, G. Noori, Carbohydr. Res. 116:303 (1983)
• M. A. Nashed & L. Anderson, J. Am. Chem. Soc. 104:7282 (1982)

---

3. § 102 anticipation assessment

What § 102 requires: a single reference disclosing (expressly, or inherently) every element of the claim, arranged as in the claim ("arranged as in the claim" standard). For a compound claim this means the reference must disclose the compound itself, or a species falling within the claim, with all claimed substituents.

My assessment, with the basis for each:

(a) US 2,252,706 (Coles) — strongest § 102-type relevance to the process aspects, not to the compound genus.
It discloses haloalkyl polyacyl glycosides and their synthesis from acyl-halo sugars + halohydrins. This corresponds closely to applicant's process (a) (reaction of formula V with alcohol IX, e.g. 3-bromo-2-bromomethyl-propan-1-ol "DlBol") and to compounds where R₁/R₂ = CH₂X. However, Coles' aglycone is a mono-halo, non-branched haloalkyl (e.g. chloroethyl, chloropropyl) — it does not disclose a 2-substituted / bis(halomethyl) propan-1-ol aglycone, nor sulfoxide/sulfone aglycones. So it would anticipate only if a claim were drawn so broadly as to read on haloalkyl glycosides generally; on the disclosed genus it is more a § 103 starting point. Assessment: potentially anticipatory only for the broadest O-glycoside/haloalkyl-glycoside claim, if one exists; more likely §103.

(b) US 3,939,145 / 4,056,322 and the Gordon family — potentially § 102 as to O-glycoside/ether general genus and intermediates, again with the same aglycone-shape caveat. They show sugar–O–Y ethers where Y is a simple functionalised alkyl group (incl. aminoalkyl). If any claim of 4,868,289 were written at the level of "a glycoside bearing a functionalised O-alkyl aglycone," Gordon would be anticipatory; but applicant's aglycone is specifically the 2-substituted propane-1,3-diyl (bis-functional) unit and its S/sox/sulfone variants, which Gordon does not show.

(c) US 4,238,473 (Lemieux) — potentially § 102 as to claims reciting "carrier" (R₅ or R₈) conjugates. Lemieux discloses oligosaccharide–protein artificial antigens. A claim reading "compound of formula I wherein R₅ is a carrier" in its broadest form could be met by Lemieux if the same aglycone/spacer chemistry were shown — which is doubtful. Assessment: likely § 102 only against an extremely broad carrier-conjugate claim; otherwise § 103.

(d) US 4,675,392 (Dahmen et al.) — the most closely related in subject matter (same research group, glycoside/neo-glycolipid chemistry, cf. the Dahmen Carbohydr. Res. papers cited in the patent). Note its grant date (1987-06-23) is after applicant's 1986-01-13 filing, so it cannot be § 102(a)/(b) art on its face; it could only matter as a § 102(e) reference (US application/patent filed before applicant's invention) if its filing date so qualifies. I could not confirm its filing date from the retrieved material.

(e) US 4,557,931 (Irie et al.) — issued 1985-12-10, i.e. after the 1985-01-14 priority date but before the 1986-01-13 US filing. I could not confirm its subject matter; based on date alone it is § 102(a)/(b) only as to the US filing date, not the foreign priority date.

---

4. Honest statement of limitations

I must be explicit about what I could not verify rather than guess:

1. Exact claim wording and numbering of US 4,868,289 were not in the retrieved text. Any statement of the form "reference X anticipates claim 3" would be fabricated. I have therefore mapped references to claim types (compound genus / polymer / process / composition) rather than numbers.
2. Titles and contents of US 3,843,626 (Sutton), US 4,557,931 (Irie et al.), and US 4,675,392 (Dahmen et al.) were not confirmed; I could not retrieve their specifications or filing dates.
3. Which references the examiner actually applied under § 102 vs. § 103 is not stated in the front-page data I retrieved. References listed under "References Cited" may have been cited for § 103 background rather than as anticipatory art. The correct way to resolve this is to read the File Wrapper / Patent Application Information Retrieval (PAIR/PatentCenter) record for App. 06/907,690, where examiner citations are marked as § 102 or § 103.
4. The user instruction mentions "the USPTO database." My results come from patents.google.com, patents.justia.com, uspto.report, and patentimages PDFs — I did not fetch the USPTO PatentCenter/PAIR record itself (I ran out of retrieval steps). The PAIR record should be consulted to confirm the examiner's statutory basis for each citation.

---

5. Bottom line

For US 4,868,289 the cited US patent art clusters into three groups:

• Haloalkyl/ether glycoside synthesis art — US 2,252,706 (Coles), US 3,843,626 (Sutton), and the Gordon family (US 3,939,145/3,939,146/3,965,262/4,016,261/4,017,608/4,056,322). These are the references with the most direct § 102-type bearing on the O-glycoside-forming process (a) and on any broadly-claimed glycoside, but none discloses the applicant's signature 2-substituted propane-1,3-diyl (bis-sulfide/sulfoxide/sulfone) aglycone.
• Conjugate/antigen art — US 4,238,473 (Lemieux), relevant to the "carrier" limitations.
• Same-field glycoside art — US 4,557,931 (Irie) and US 4,675,392 (Dahmen), the latter by the applicant's own co-workers and thus the closest in subject matter; US 4,675,392 can only be prior art via § 102(e) given its later grant date.

To make the § 102 determination defensible claim-by-claim, the next step is to pull the full claim set of US 4,868,289 plus the PAIR prosecution record and the complete texts of US 3,843,626, US 4,557,931, and US 4,675,392.

I'll research the prior art landscape around this 1985-priority glycoside/glycolipid patent before building the obviousness analysis.

Obviousness Analysis — U.S. Patent No. 4,868,289 ("Glycosidic derivatives") under 35 U.S.C. § 103

0. Scope, sources, and an important caveat

Caveat on claim text. The authoritative full text supplied for this analysis (from https://patents.google.com/patent/[US4868289](/patent/US4868289)/en) terminates mid-word in the specification ("Fo") and does not include the "What is claimed is" claim set. I therefore organize this analysis by the subject matter the specification itself presents as claimed (the Formula I genus, its enumerated subgenera, the polymers of formulas XX/XXI, processes (a)–(j), and the pharmaceutical/diagnostic compositions), and I flag where a claim-specific conclusion would require the actual claim language. Where I say "likely obvious," the reader should treat that as conditional on the claim text being as the specification describes.

"Prior art section of this page." The Google Patents record for US4868289A supplies (i) the "Prior art keywords" field — sub, compound, rso, cooch, formula — and (ii) the specification's "Description of the Prior Art" and in-text citations, which are the applicant's own statement of the art. That in-text citation set is the anchor for this analysis. I have supplemented it only with the patent documents that those citations identify by name (the Lemieux bridging-arm family), and with the full bibliographic identity of the applicant-cited journal papers, which I retrieved. Where I could not retrieve a document's full text, I say so.

Applicable law. Because the application (06/907,690, filed 1986‑01‑13, PCT/DK86/00006 § 371 date 1986‑09‑03, priority DK 1985‑01‑14) predates 2013‑03‑16, pre‑AIA 35 U.S.C. §§ 102/103 govern. Key consequence: the § 102(b) statutory-bar critical date is one year before the U.S. filing date (1986‑01‑13) → 1985‑01‑13, and foreign priority does not move the § 102(b) critical date. All of the applicant-cited 1983–1984 publications fall before that date and are therefore § 102(b) statutory bars, not merely § 102(a) art.

---

1. Legal framework

• Graham v. John Deere Co., 383 U.S. 1 (1966): scope and content of the prior art; differences between prior art and claims; level of ordinary skill; and secondary considerations.
• KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007): "the combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results"; where there is "an apparent reason to combine the known elements in the fashion claimed," § 103 is satisfied; a finite number of identified, predictable solutions yields the "obvious to try" conclusion; and design incentives/market forces (and the background knowledge of the artisan) supply the motivation.
• In re O'Farrell, 853 F.2d 894 (Fed. Cir. 1988): "obvious to try" is enough in a predictable art when there are a finite number of parameters to be varied.
• In re Kollar / In re Petering: the enumeration of a limited class of known alternatives (e.g., a list of standard saccharide residues) is an obvious selection, not a patentable one.
• In re Schreiber, 128 F.3d 1453 (Fed. Cir. 1997): a functional recitation of intended use does not impart patentability to an otherwise obvious composition.

This is a predictable art (synthetic carbohydrate/organic chemistry). The claims are largely structural genus claims over a small set of chemically obtained molecules plus the process steps by which they are made. That posture makes the combination case here strong.

---

2. Person of ordinary skill in the art (PHOSITA)

A PHOSITA at the 1985 priority date would be:

• a synthetic organic/carbohydrate chemist with a Ph.D. and ~2–4 years' post-doctoral experience in oligosaccharide or glycoconjugate synthesis (or an M.S. with substantially more experience);
• familiar with glycosylation methodology (Koenigs–Knorr and orthoester/oxazoline/thioglycoside donors; BF₃·Et₂O, silver triflate, HgBr₂/Hg(CN)₂ promotion), protecting-group strategy (acetyl, benzoyl, benzyl, benzylidene, phthalimido), thiol–halide nucleophilic displacement, peracid oxidation of sulfides, and coupling of glycosides to proteins and solid supports; and
• aware of the contemporary literature on synthetic "neo-glycolipids"/"neo-glycoproteins" (Rando/Slama; Lemieux; Dahmén et al.) and of the glycobiology literature (Sharon & Lis; Hakomori; Beachey).

The specification itself confirms that the relevant chemistry is routine: it recites oxidation agents ("peracids, e.g. m‑chloroperbenzoic acid; peroxides, e.g. tert.butyl hydroperoxide; aminooxides, gaseous oxygen... potassium permanganate, chromium trioxide"), bases ("cesium carbonate, potassium carbonate, sodium carbonate... pyridine"), and catalysts ("BF₃·Et₂O or SnCl₄... silver oxide, silver carbonate, silver triflate, HgBr₂, Hg(CN)₂") as known reagents—an implicit admission of the ordinary skill level.

---

3. The claimed subject matter, distilled

Formula I core architecture. (Sugar)ₙ–O–CH₂–CH(R¹)(R²), optionally with R²/R³ together being ═CH₂. In words: an O‑glycoside whose aglycon is a 1‑oxygenated propane‑1,3‑diyl unit bearing two substituents at C‑2. Where R¹ and R² are CH₂–S(O)_m(O)_p–R⁴–R⁵ with R⁴ = C₁₆ alkyl and R⁵ = CH₃, the compounds are "bis‑thio," "bis‑sulfoxide," or "bis‑sulfone" glycolipids with two lipophilic tails. Where R⁵ = COOCH₃/COOH/NH₂/carrier, they are spacer‑arm glycosides.

Claim‑relevant categories (per the specification):

1. Genus: Formula I compounds (all Sugar/R¹/R²/R³/R⁴/R⁵ permutations).
2. Subgenus: R¹ = R² = CH₂X (X = leaving group, preferably Br) — the "DIBol" glycosides.
3. Subgenus: R¹ = R² = formula II (thioether/sulfoxide/sulfone with terminal functional group).
4. Subgenus: R²R³ = ═CH₂ (allyl-thio / allylic glycosides).
5. Subgenus: R¹ = formula III (–CH₂–O–R⁶) or IIIa (glyceryl diether with C₈–C₁₈ alkyl).
6. Formula IV: –CH₂–carrier (BSA, KLH, silica gel, etc.).
7. Polymers XX (linear, dithio-linked) and XXI (three-dimensional, trithio-linked).
8. Processes (a)–(j).
9. Pharmaceutical/diagnostic compositions and methods of use (antiviral/antibacterial prophylaxis, diagnostics, vaccines, contraceptives).

The two structural design moves that define the alleged invention:

• Add a second hydrophobic tail and put it on a branched C‑3 (glycerol-like) scaffold — i.e., convert the art-known linear –O–CH₂–CH₂–Br aglycon into –O–CH₂–CH(CH₂X)(CH₂X) and displace both X's.
• Vary the sulfur oxidation state and the tail terminus to tune amphiphilicity and to provide carrier attachment handles.

Both moves are squarely within the finite, predictable design space the prior art had already established.

---

4. Prior art of record (with what each reference teaches)

Applicant's own admissions in the Background (verbatim), which fix the problem and the motivation:

"Unnatural glycoconjugates (so-called neo-glycoconjugates) have been prepared both as neo-glycolipids (cf. Slama & Rando (1980) and Dahmen et al. (Carbohydr. Res., 127, 1984))… No neo-glycolipids having a close molecular similarity to the natural compound have, however, yet been prepared."

Natural glycolipids are shown as glycosphingolipids (sphingosine + fatty acid = two chains) and glycoglycerolipids (glycerol + two fatty acid chains).

"It is known that the chemical structure of the hydrophobic part of lipids determines the type of aggregates that can be formed (micelles, liposomes, etc.)…" (Israelachvili).

These are judicial admissions that (a) the art already made single-tail/lipid-anchored neoglycolipids, (b) the art recognized that a close structural mimic of natural glycolipids had not yet been made, and (c) natural glycolipids are two-chain lipids built on glycerol or sphingosine. That is a complete problem statement with an obvious architectural answer.

---

5. The § 103 combinations

Combination A — The bis-thio glycolipid core (claims to R¹ = R² = CH₂S–R⁴–R⁵, R⁴ long alkyl, R⁵ = H/CH₃)

References combined: PA‑5 and PA‑6 (Dahmén et al. 1984, Carbohydr. Res. 127) in view of PA‑1 (Slama & Rando 1980 / Rando et al. 1980) and PA‑10 (Israelachvili 1980).

What the combination yields. PA‑5/PA‑6 disclose, in terms, an O‑glycoside of the structure Sugar–O–CH₂–CH₂–S–C₁₈H₃₇ (plus the –(CH₂)₂COOCH₃ and –(CH₂)₁₀COOCH₃ homologues) made by BF₃‑catalyzed glycosylation with 2‑bromoethanol followed by thiol displacement. The claimed compounds are the same compounds with one extra CH₂–S–R tail branch at C‑2, i.e. Sugar–O–CH₂–CH(CH₂SR)(CH₂SR).

Motivation (explicit and specific):

1. The Background states the goal: a neo‑glycolipid with "close molecular similarity to the natural compound."
2. The Background's own structural diagrams show that the natural compound's hydrophobe is two-tailed (sphingosine + fatty acid; glycerol + 2 fatty acids).
3. PA‑1 teaches that the sugar must be held away from the membrane on a lipid anchor, and that anchor structure governs function; PA‑10 teaches that the hydrophobic portion's structure controls aggregation and membrane behavior.
4. A PHOSITA would therefore seek a two-tail, glycerol-like scaffold — which is exactly the –O–CH₂–CH(CH₂–)–CH₂– unit. The aglycon of Formula I is, structurally, the glycerol backbone of a glycoglycerolipid with the two hydroxyls replaced by CH₂–S–tails and the glycosidic oxygen at C‑1. Put differently, the invention is the thioglycoside isostere of a natural glycoglycerolipid.
5. The chemistry needed to get there is the identical thiol–halide displacement of PA‑3/PA‑5, merely applied to a doubly benzylic/primary dihalide X–CH₂–CH(CH₂X)–CH₂–O–Sugar instead of the mono-halide of the art. The reagent (3‑bromo‑2‑bromomethylpropan‑1‑ol, "DIBol") is the applicant's own copending subject matter and is itself an obvious C‑3 homologation of the art's 2‑bromoethanol.

Reasonable expectation of success. Very high. The only variables are (i) tail count, (ii) tail length, and (iii) sulfur oxidation state — a finite, predictable set. Increasing the number and length of hydrocarbon tails increases membrane affinity/micelle-forming tendency, a textbook structure–property relationship the specification itself invokes via Israelachvili.

§ 103 conclusion: the bis‑thio glycolipid subgenus is likely obvious as a matter of law under KSR (a known reaction on a known type of substrate, with a known structural aim, yielding a predictable result). The only genuinely inventive-looking element — the choice of a branched C‑3 scaffold bearing two thio tails — is precisely the structure the prior art's own statement of the problem pointed to.

---

Combination B — The bis-sulfoxide and bis-sulfone subgenera

References: Combination A (bis‑thio glycolipids) + the routine oxidation of sulfides with peracids/peroxides (expressly enumerated in the specification: "peracids, e.g. m‑chloroperbenzoic acid; peroxides, e.g. tert.butyl hydroperoxide; aminooxides, gaseous oxygen, or inorganic oxidizing agents such as potassium permanganate, chromium trioxide").

Motivation: The specification supplies its own reason: "Through the use of sulfoxide or sulfone groups in the molecule, it is possible to 'fine-tune' the hydrophilic/hydrophobic and polar/apolar properties of the aglycon moiety," and (for the COOH/sulfone combination) "these compounds are water soluble while at the same time they are 'mimics' of natural glycolipids." Oxidation of a thioether to the sulfoxide/sulfone with m‑CPBA is among the most well-known transformations in organic chemistry (its stoichiometry — 2 eq. for sulfoxide, ≥4 eq. for sulfone — is recited in the specification as a known parameter).

Obviousness: an artisan who has made the bis‑thio compound and who knows that sulfoxides/sulfones modulate polarity and water solubility would obviously oxidize it. The claimed sulfone glycolipids (GalO–CH₂–CH(CH₂SO₂C₁₆H₃₃)₂, etc.) are the predicted product of applying a one‑step, high‑yield, standard oxidation to a compound the artisan already had. Likely obvious.

---

Combination C — Spacer-arm and carrier subgenus (R⁵ = COOR¹⁰, COOH, NH₂, carrier; Formula IV; conjugates to BSA/KLH/silica)

References: PA‑7 (Lemieux '401) + PA‑8 (Lemieux '473) + PA‑9 (Lemieux '174 / EP 0 044 188) + PA‑4/PA‑5/PA‑6 (Dahmén 1983/1984).

What the combination yields. Lemieux '401/'473 teach an O‑glycosidic linking arm of C₃–C₁₇ aliphatic hydrocarbon terminated by H, OH, NH₂, NHNH₂, N₃ or lower alkoxy, used to attach carbohydrate determinants to carriers and solid supports to make artificial antigens and immunoadsorbents. Dahmén 1983–84 teach the thioether version of the same idea: Sugar–O–CH₂CH₂–S–(CH₂)₂COOCH₃ and –S–(CH₂)₁₀COOCH₃, and their coupling to BSA and KLH. The claimed spacer subgenus (R⁴ = (CH₂)₂ or (CH₂)₁₀, R⁵ = COOCH₃/COOH/NH₂/carrier) is the product of applying the Lemieux bridging-arm concept and the Dahmén thiol-displacement chemistry to the two-tail core of Combination A — which is exactly what the specification's own Examples 3–6 do (RSO₂C10E‑2, hydrolysis to RSO₂C10A, the spermidine conjugate, the aminated‑silica conjugate, and the BSA conjugate).

Motivation: (i) attaching sugars to carriers to elicit antibodies and to make immunoadsorbents was the express purpose of PA‑7/PA‑8; (ii) Dahlmén's neoglycoproteins (PA‑4/PA‑5/PA‑6) had already coupled the (CH₂)₂/₁₀COOCH₃-terminated thio spacers to BSA and KLH; (iii) the applicant's stated object of providing synthetic receptors "for therapy or prophylaxis" and "as research chemicals" makes a carrier handle self-evidently desirable.

Obviousness: Strongly likely obvious. Notably, the specification's own claim-support for the "carrier" definition — globulins, albumins (BSA), fibrins, polylysin, KLH; polysaccharides such as cellulose, starch, chitosan, aminated Sepharose; plastics (aminated latex, thiolated/aminated/hydroxylated polystyrene, polyvinyl alcohol); and inorganic materials (silica gel, glass, aluminium oxide) — is a recitation of Lemieux's and Dahmén's known carrier set.

---

Combination D — Allyl-thio / allylic subgenus (R²R³ = ═CH₂)

References: Combination A + the known base‑mediated dehydrohalogenation of 1,3‑dihalogenated propane derivatives → allylic halides, + PA‑12 (Birch & Walker 1967).

Analysis. The specification's process (c) is base‑promoted elimination of HX from the bis‑halide monomer to give a CH₂=C(CH₂X)– allylic glycoside, and processes (d)–(f) add thiol/alcohol/amine across the allylic system. Base‑catalyzed dehydrohalogenation to give the more reactive allylic halide is routine (the specification itself lists Cs₂CO₃, K₂CO₃, NaOH, KOH, pyridine and stronger bases such as NaH or butyllithium). The specification recites the motivation directly ("Allyl-thio compounds have the advantage of being easily hydrogenated… applied to the allyl‑thio glycosides of the present invention for radioactive labelling with catalytic tritiation"), citing PA‑12.

Obviousness: the genus of allylic glycosides is likely obvious as an intermediate/alternative; a PHOSITA seeking a selectively monofunctionalizable difunctional aglycon (to leave one arm free for a carrier or a second, different tail) would routinely exploit the greater reactivity of an allylic halide. This subgenus is the weakest part of the applicant's case against § 103, and any nonobviousness argument must rest on the specific substitution patterns and products, not the mere existence of the allylic intermediate.

---

Combination E — Polymers of formulas XX and XXI

References: Combination A + the known reaction of a dihalide with a dithiol (formula XX) or a trithiol (formula XXI), in the presence of a mild base.

Motivation: (i) the specification states that process (g)/(h) uses "reaction conditions… similar to those described in the thio‑ether‑forming step in process (b)" — i.e. the same known chemistry; (ii) the general and long-standing incentive in glycobiology to present many carbohydrate haptens on one scaffold (multivalency/"cluster effect," and the carrier-conjugation teaching of PA‑8) makes a carbohydrate‑functionalized polymer an obvious target; (iii) polyfunctional thiols as crosslinkers/chain extenders are standard polymer chemistry.

Obviousness: Likely obvious under KSR's "known element combined with known element using a known method for its intended purpose." The formula XXI 3‑D network is the mere geometric consequence of stoichiometry (2 reactive sites on the monomer, 3 on the trithiol), which the specification itself explains.

---

Combination F — Process claims (a)–(j)

Conclusion on process claims: absent some unexpected result attributable to the choice of a particular reagent (and none is disclosed), processes (a)–(j) are likely obvious. Process claims of this kind usually survive only by capturing a specific, non‑routine reaction parameter; the enumeration here reads as a recitation of known carbohydrate methodology.

---

Combination G — Compositions and methods of use

References: PA‑8 (Lemieux '473 — artificial antigens, immunoadsorbents, antigen detection) + PA‑11 (Hansson et al. 1984 — virus‑overlay binding assay) + PA‑13 (Sharon & Lis; Beachey — carbohydrate receptors mediate microbial/viral attachment) + PA‑2 (Rando/Slama — sugar–lipid conjugates functional in membranes).

Analysis. The specification's asserted utilities are (i) binding and neutralizing viruses/bacteria at mucosal ports of entry; (ii) RIA‑/ELISA‑based diagnostics and dip‑sticks/blood‑test cards; (iii) vaccines/antigens; (iv) contraception. Each is a functional statement of intended use appended to the same compounds. Under In re Schreiber, such statements cannot rescue an otherwise obvious composition. Moreover, PA‑8 already teaches attaching carbohydrate haptens to carriers and supports for antigen detection and antibody isolation, PA‑11 already supplies the virus‑binding assay (which the applicant adopts wholesale in Example 8), and the glycobiology literature already established the receptor role of cell‑surface carbohydrates. Competitive inhibition of microbial attachment by an administered soluble receptor analog is a predictable therapeutic strategy once the receptor analog is in hand. Likely obvious to the extent these claims merely recite known uses of the compounds.

---

6. Anticipation vs. obviousness (a distinction worth stating)

The Lemieux bridging-arm species (O–R–COR″, R = linear aliphatic C₃–C₁₇) and the Dahmén species (Sugar–O–CH₂CH₂–S–(CH₂)ₙCOOCH₃; Sugar–O–CH₂CH₂–SC₁₈H₃₇) each lack the C‑2 branch bearing the second tail/function, so they do not appear to anticipate Formula I under § 102. The case against the patent is therefore a § 103 case built on the branch point — and, as shown above, the branch point is exactly the feature the art's own statement of the problem pointed to.

A caveat: if the granted claims are limited to, or include, specific species whose second arm is absent or trivial, or which read on the applicant's admitted prior art (e.g., a Formula I compound in which R² = H falls outside the claims; but if a claim recites R¹ = R², the art species are excluded), then anticipation analysis would have to be re‑run species-by-species.

---

7. Secondary considerations and the applicant's best rebuttals

The applicant has two credible nonobviousness arguments; both are colorable but both are vulnerable.

(1) Unexpected liquid‑crystal formation in an aprotic medium. The specification asserts: bis‑sulfide glycolipids (RSC16‑8, RSC16‑9, RSC16‑12) "form liquid crystals in aprotic media such as dimethyl sulphoxide… To the best of Applicant's knowledge, this is the first time that liquid crystals have been prepared in an aprotic medium, and this particular property may render possible the formation of liquid crystals with higher stability in electrical fields."

• Strength: if proven, a newly discovered property not predictable from the art can rebut § 103 (In re Papesch doctrine; WBIP v. Kohler for objective indicia) — but only if a nexus exists between the property and the claimed structure, and only if the property would not have been expected from the close prior art.
• Weakness: the assertion is qualified ("to the best of Applicant's knowledge," "conceivably"), is supported by a single qualitative observation (Example 7, polarizing microscope, "preferentially in the vicinity of entrapped bubbles"), and — critically — the specification never claims liquid crystals or a liquid‑crystal device. A property that is not reflected in the claims rarely carries weight, because the claimed invention is the compound, and the compound was obvious. Also, amphiphiles with two long chains are the classic mesogens; mesophase formation from a two‑tail amphiphile is not a surprising result, which undercuts the "unexpected property" framing.
• Practical effect: this is the strongest lever the applicant has, but a § 103 challenger would argue it is (a) attorney argument unsupported by comparative data, (b) not commensurate with the claim scope (the claim genus covers thousands of compounds, none of which were tested for mesophase behavior), and (c) an inherent property of the class that a PHOSITA would have expected from a promesogenic two‑chain amphiphile.

(2) Water‑soluble sulfone/spacer glycolipids that still mimic natural receptors. The specification asserts a "new physical property": compounds in which R¹ = –CH₂–S(O)_m(O)_p–R⁴–COOH and R² = –CH₂–S(O)_m(O)_p–R⁴–CH₃/COOH are water‑soluble yet receptor‑active (see the virus‑binding data and Example 8/9).

• Strength: the data in Example 8/9 (ELISA with Sendai virus; compounds A and B compared against natural Galβ‑ceramide and Glcβ‑ceramide) is genuine comparative data showing receptor mimicry.
• Weakness: water solubility is not a claimed property; it is a consequence of putting a carboxylic acid and two sulfone groups on the molecule, which is exactly the predictable outcome of Combination B (oxidation raises polarity) plus the known (CH₂)ₙCOOH terminus of PA‑6. The activity data establishes utility, not nonobviousness — the compounds still had to be made, and they were made by the obvious route. There is no showing that the claimed genus as a whole (sugars, tail lengths, oxidation states) behaves this way.

Other objective indicia (unlikely to help): no evidence of commercial success, licensing, copying, industry praise, or long‑felt but unmet need appears in the record; the patent lapsed for non‑payment of maintenance fees in 2006 (Expired – Fee Related) with no litigation history — consistent with a patent that never acquired commercial significance.

---

8. Bottom line

The § 103 case against U.S. 4,868,289 is strong, and the primary combination is unusually clean because it is built from the applicant's own admissions and the applicants' own prior publications.

Primary combination: Dahmén et al., Carbohydr. Res. 127:15–26 and 127:27–33 (1984), and Carbohydr. Res. 125:237–245 (1984) (single‑tail 2‑thioethyl lipid/spacer‑arm O‑glycosides made by thiol displacement on a 2‑bromoethyl glycoside, plus coupling to BSA/KLH) *in view of Slama & Rando, Biochemistry 19:4595 (1980) / Rando et al., PNAS 77:2510 (1980)* (synthetic glycolipids: sugar + spacer + lipid anchor; anchor structure governs receptor function) and Israelachvili et al. (1980) (the hydrophobe's structure dictates aggregation and membrane behavior), further in view of Lemieux U.S. Pat. Nos. 4,137,401, 4,238,473 and 4,195,174 (O‑glycosidic C₃–C₁₇ linking arms terminated by H/OH/NH₂/NHNH₂/N₃/alkoxy, for attaching carbohydrate haptens to carriers and solid supports to make artificial antigens and immunoadsorbents).

Motivation, in the applicant's own words and pictures: the art had already made neo‑glycolipids but "no neo-glycolipids having a close molecular similarity to the natural compound have… yet been prepared"; the natural compounds depicted in the Background are two‑chain lipids built on glycerol or sphingosine. The claimed aglycon –O–CH₂–CH(CH₂–)₂ is the glycerol backbone with the two hydroxyls replaced by thio tails. The only structural departure from the closest art (add a branch at C‑2, put a second thio tail on it) is a predictable variation; the only chemical departure (displace two bromides instead of one) uses the identical known reaction (PA‑3/PA‑5).

Secondary combinations:

• Oxidation of the bis‑thio compounds with m‑CPBA/peroxides → the bis‑sulfoxide and bis‑sulfone subgenera (motivated by the applicant's own "fine‑tuning" rationale).
• Lemieux/Dahmén carrier chemistry → the (CH₂)₂/₁₀COOCH₃/COOH/NH₂/carrier spacer subgenus and the BSA/KLH/silica conjugates.
• Base‑mediated dehydrohalogenation (+ Birch & Walker 1967) → the allylic/allyl‑thio subgenus.
• Dithiol/trithiol polymerization → formulas XX and XXI.
• Lemieux '473 + Hansson et al. 1984 + Sharon & Lis/Beachey → the composition and method‑of‑use claims.

The only serious nonobviousness lever is the asserted, asserted‑only, unclaimed liquid‑crystal formation of the bis‑sulfide glycolipids in aprotic media — and even that is qualified in the specification, unreduced to practice in the claims, and arguably an inherent property of a two‑tail promesogenic amphiphile. It is not, on the present record, enough to save the generic compound claims.

Confidence: high on the direction of the § 103 conclusion (obvious) for the compound, polymer, process, and composition claims as the specification describes them; moderate on the claim‑by‑claim outcome, because the actual claim language of 4,868,289 is not present in the authoritative record supplied, and I could not retrieve the patent's examiner‑cited "References Cited" table nor the full text of several of the applicant‑cited papers. If the actual claims contain a limitation not discussed here (for example a specific defined oxidation‑state/tail‑length combination coupled to an asserted property, or a product‑by‑process limitation), the analysis should be re‑run against that limitation before any validity opinion is given. The bibliographic and technical content of every reference cited above is drawn from the sources hyperlinked in § 4; where a source is a secondary summary (e.g., the documentsdelivered abstracts for PA‑5/PA‑6), the primary journal text was not directly retrieved and should be checked before filing.